Citations

Mayo Clinic

Showing 10 of 108572 citations.

Telehealth and Technology
Petersen, Carolyn , Reid, Sonya , Petersen, Carolyn , Yu, James B. , Rosenbloom, S. Trent , Warner, Jeremy L.

The Cancer Journal | January 24, 2024 | Volume: 30 | Issue: 1 | Pages: 40-45

10.1097/ppo.0000000000000692 | PMID 38265926 Get It

Abstract Telehealth is a broad concept that refers to any delivery of health care in real time using technologies to connect people or information that are not in the same physical location. Until fairly recently, telehealth was more aspiration than reality. This situation changed radically due in part to the COVID-19 pandemic, which led to a near-overnight inability for patients to be seen for routine management of chronic health conditions, including those with cancer. The purpose of this brief narrative review is to outline some areas where emerging and future technology may allow for innovations with specific implications for people with a current or past diagnosis of cancer, including underserved and/or historically excluded populations. Specific topics of telehealth are broadly covered in other areas of the special issue.
Kidney after Liver Transplantation for All
Kumar, Abhishek , Wadei, Hani M. , Wadei, Hani M

Clinical Journal of the American Society of Nephrology | January 24, 2024 | Volume: 19 | Issue: 3 | Pages: 289-291

10.2215/cjn.0000000000000409 | PMID 38265809 Get It

Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020
Davidson, Tara M. , Glasgow, Amy E. , Yan, Yiyi, Hieken, Tina J. , Habermann, Elizabeth B.

Melanoma Research | January 24, 2024 | Volume: 34 | Issue: 2 | Pages: 175-181

10.1097/cmr.0000000000000953 | PMID 38265469 Get It

Melanoma diagnosed within 1 year of pregnancy is defined as pregnancy-associated melanoma (PAM). No robust data on how pregnancy influences melanoma nor guidelines for PAM management exist. With IRB approval, female patients with a pathology-confirmed melanoma diagnosis within 1 year of pregnancy treated at our institution from 2000 to 2020 were identified. Controls from the cancer registry were matched 1 : 4 when available on decade of age, year of surgery (±5), and stage. We identified 83 PAM patients with median follow-up of 86 months. Mean age at diagnosis was 31 years. 80% AJCC V8 stage I, 2.4% stage II, 13% stage III, 4.8% stage IV. Mean Breslow thickness was 0.79 mm and 3.6% exhibited ulceration. The mean mitotic rate was 0.76/mm 2 . In terms of PAM management, 98.6% of ESD patients and 86.7% of LSD patients received standard-of-care therapy per NCCN guidelines for their disease stage. No clinically significant delays in treatment were noted. Time to treatment from diagnosis to systemic therapy for LSD patients was an average of 46 days (95% CI: 34–59 days). Comparing the 83 PAM patients to 309 controls matched on age, stage, and year of diagnosis, similar 5-year overall survival (97% vs. 97%, P = 0.95) or recurrence-free survival (96% vs. 96%, P = 0.86) was observed. The outcomes of PAM following SOC treatment at a highly specialized center for melanoma care were comparable to non-PAM when matched by clinical-pathologic features. Specialty center care is encouraged for women with PAM.
Mechanical and morphometric analysis of the third carpal bone of Thoroughbreds
Young, David R., Richardson, Dean W. , Markel, Mark D., Nunamaker, David M.

American Journal of Veterinary Research | January 24, 2024 | Volume: 52 | Issue: 3 | Pages: 402-409

10.2460/ajvr.1991.52.03.402 Get It

SUMMARY The third carpal bone (C 3 ) was collected from both forelimbs of 27 Thoroughbreds. On the basis of age, training, and history, specimens were assigned to 1 of 5 groups: yearling, untrained horses (group 1, n = 4); 2- to 3-year-old, untrained horses (group 2, n = 7); trained 2-year-old horses (group 3, n = 6); trained 3-year-old horses (group 4, n = 6); and 3-year-old, trained horses with carpal pathologic features (group 5, n = 4). A transverse section of subchondral bone 5-mm thick was cut in a precise fashion 10 mm below the proximal articular surface of all specimens. After high-detail radiography was done, indentation testing was performed on the proximal surface of the section at points 5 mm apart. The stiffness of the subchondral cancellous bone was determined from the slope of the load vs displacement curve. Topographic plots of stiffness measurements were compared with radiographs of each specimen. Point determinations were averaged to derive measures for the radial and intermediate facets, and for regions 5, 10, 15, and 20 mm from the dorsal margin of C 3 . Area fraction (1-p; p = porosity) was measured for the radial and intermediate facets, using an automated image analysis system. Significant ( P < 0.05) increases in stiffness and area fraction were found in the C 3 from trained horses (groups 3 to 5), compared with untrained horses (groups 1 to 2). Stiffness and area fraction of the radial facet of pathologic C 3 were significantly higher than the same variables measured in C 3 from any other group. A typical profile of regional subchondral stiffness was identified in C 3 from normal horses, with maximal stiffness measured 10 mm from the dorsal articular margin. A different pattern was found in pathologic C 3 , with significantly greater stiffness 15 and 20 mm from the dorsal articular margin when compared with normal horses. A highly significant ( P < 0.0001) direct linear correlation between stiffness and area fraction at the radial facet was found. Topographic and radiographic analysis demonstrated good correlation between stiffness and radiographic density of the bone sections. The observed patterns of normal and pathologic C 3 were contrasted. In particular, a large gradient in subchondral stiffness was identified in pathologic C 3 at the dorsomedial aspect of the bone.
Fracture Risk Among Living Kidney Donors 25 Years After Donation
Miller, Adam R. , Kasiske, Bertram L. , Matas, Arthur J. , Kremers, Walter K. , Kremers, Walter K , Kremers, Hilal Maradit , Grossardt, Brandon R. , Kasiske, B.L. , Khosla, Sundeep , Amer, Hatem , Kumar, Rajiv

JAMA Network Open | January 24, 2024 | Volume: 7 | Issue: 1 | Pages: e2353005

10.1001/jamanetworkopen.2023.53005 | PMID 38265798 Get It

Importance Living kidney donors may have an increased risk of fractures due to reductions in kidney mass, lower concentrations of serum 1,25-dihydroxyvitamin D, and secondary increases in serum parathyroid hormone. Objective To compare the overall and site-specific risk of fractures among living kidney donors with strictly matched controls from the general population who would have been eligible to donate a kidney but did not do so. Design, Setting, and Participants This survey study was conducted between December 1, 2021, and July 31, 2023. A total of 5065 living kidney donors from 3 large transplant centers in Minnesota were invited to complete a survey about their bone health and history of fractures, and 16 156 population-based nondonor controls without a history of comorbidities that would have precluded kidney donation were identified from the Rochester Epidemiology Project and completed the same survey. A total of 2132 living kidney donors and 2014 nondonor controls responded to the survey. Statistical analyses were performed from May to August 2023. Exposure Living kidney donation. Main Outcomes and Measures The rates of overall and site-specific fractures were compared between living kidney donors and controls using standardized incidence ratios (SIRs). Results At the time of survey, the 2132 living kidney donors had a mean (SD) age of 67.1 (8.9) years and included 1245 women (58.4%), and the 2014 controls had a mean (SD) age of 68.6 (7.9) years and included 1140 women (56.6%). The mean (SD) time between donation or index date and survey date was 24.2 (10.4) years for donors and 27.6 (10.7) years for controls. The overall rate of fractures among living kidney donors was significantly lower than among controls (SIR, 0.89; 95% CI, 0.81-0.97). However, there were significantly more vertebral fractures among living kidney donors than among controls (SIR, 1.42; 95% CI, 1.05-1.83). Conclusions and Relevance This survey study found a reduced rate of overall fractures but an excess of vertebral fractures among living kidney donors compared with controls after a mean follow-up of 25 years. Treatment of excess vertebral fractures with dietary supplements such as vitamin D 3 may reduce the numbers of vertebral fractures and patient morbidity.
Automated Identification of Key Steps in Robotic-Assisted Radical Prostatectomy Using Artificial Intelligence
Khanna, Abhinav, Antolin, Alenka, Bar, Omri , Ben-Ayoun, Danielle, Zohar, Maya, Boorjian, Stephen A. , Frank, Igor, Shah, Paras , Sharma, Vidit , Thompson, R. Houston, Wolf, Tamir, Asselmann, Dotan, Tollefson, Matthew K. , Tollefson, Matthew

Journal of Urology | January 24, 2024 | Volume: 211 | Issue: 4 | Pages: 575-584

10.1097/ju.0000000000003845 | PMID 38265365 Get It

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
Aggarwal, Rahul , Hillman, David W. , Xiao, Han , Picus, Joel , Taplin, Mary‐Ellen , Dorff, Tanya B. , Appleman, Leonard J. , Weckstein, Douglas, Patnaik, Akash , Bryce, Alan H. , Shevrin, Daniel H. , Mohler, James L. , Anderson, D. Mark , Tan, Alan , Halabi, Susan , Dooley, Katharine , O’Brien, Patrick, Ryan, Charles J. , Eggener, Scott E. , Dakhil, Shaker R. , Smith, Raymond E., Gartrell, Benjamin A. , Fagbemi, Seth O., Mowat, Rex B., Hashemi, Neda , Humeniuk, Michael, Ellerton, John , Olsen, Mark R., Wang, Jennifer , Pascual, Sheila, Randall, James M., Kilari, Deepak , Najera, Jose Eugenio, Rowland, Kendrith M. , Hauke, Ralph J. , Shehadeh, N. J., Curti, Brendan D. , Sheh, Bryant C., Basnet, Alina , Gross, Howard M., Hillman, David W , Xiao, Han , Picus, Joel , Dorff, Tanya , Appleman, Leonard , Patnaik, Akash , Bryce, Alan H , Shevrin, Daniel , Mohler, James , Rao, Arpit , Tagawa, Scott T , Halabi, Susan , Dooley, Katharine , O'Brien, Patrick, Chen, Ronald , Eggener, Scott , Morris, Michael J , Heller, Glenn , Anderson, Daniel, Tagawa, Scott T. , O'Brien, Patrick, Chen, Ronald C. , Morris, Michael J. , Kim, Charles , Whang, Young E. , Farber, Charles R. , King, David, Monk, Paul , Bitting, Rhonda L. , Gupta, Gopal N. , Collins, Timothy, Beer, Tomasz M. , Tate, David J. , Conway, James, Goodman, Michael Moses

Journal of Clinical Oncology | January 24, 2024 | Volume: 42 | Issue: 10 | Pages: 1114-1123

10.1200/jco.23.01157 | PMID 38261983 Get It

PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen receptor antagonist, and abiraterone acetate plus prednisone (AAP) prolong survival in the metastatic setting. We evaluated whether intensification of androgen-deprivation therapy (ADT) improves outcomes in BRPC. PATIENTS AND METHODS PRESTO is a randomized phase III, open-label trial in patients with BRPC and PSA doubling time ≤9 months (ClinicalTrials.gov identifier: NCT03009981 ). Patients were randomly assigned 1:1:1 to receive a finite 52-week treatment course with ADT control, ADT + apalutamide, or ADT + apalutamide + AAP. The primary end point was PSA progression-free survival (PSA-PFS), defined as serum PSA >0.2 ng/mL after treatment completion. RESULTS Five hundred three patients were enrolled. The median PSA was 1.8 ng/mL (IQR, 1.0-3.6). At the first planned interim analysis, both experimental arms significantly prolonged PSA-PFS compared with the control arm (median, 24.9 months for ADT + apalutamide v 20.3 months for ADT; hazard ratio [HR], 0.52 [95% CI, 0.35 to 0.77]; P = .00047; median, 26.0 months for ADT + apalutamide + AAP v 20.0 months for ADT; HR, 0.48 [95% CI, 0.32 to 0.71]; P = .00008). Median time to testosterone recovery did not differ across treatment arms. The most common grade ≥3 adverse event was hypertension (7.5%, 7.4%, and 18% in ADT, ADT + apalutamide, and ADT + apalutamide + AAP arms, respectively). CONCLUSION Intensified AR blockade for a finite duration prolongs PSA-PFS with a manageable safety profile, without adversely affecting time to testosterone recovery. The addition of apalutamide to ADT should be considered in patients with high-risk BRPC.
Reversal of Cerebral Arteriopathy Post-Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Booth, Natalie , Ngwube, Alexander , Shah, Sanjay , Abruzzo, Todd , Appavu, Brian

Pediatrics | January 24, 2024 | Volume: 153 | Issue: 2 | Pages: No page available

10.1542/peds.2023-062643 | PMID 38263886 Get It

Sickle cell disease (SCD) is a chronic hematologic disorder which causes progressive cerebral arteriopathy beginning in childhood. As a result, arterial ischemic stroke is a major cause of morbidity and mortality in SCD, and SCD is a leading cause of childhood stroke worldwide. Allogenic hematopoietic stem cell transplant (HSCT) may be curative for individuals with SCD. Long-term outcomes and effects are currently being studied. In this report, we describe a child with SCD who presented with arterial ischemic stroke at 6 years of age and was found to have a severe form of cerebral large vessel arteriopathy by catheter-directed angiography. The patient initially underwent revascularization surgery by indirect superficial temporal artery to middle cerebral artery bypass, and 1 year later, he underwent curative HSCT. Approximately 3 years after HSCT, repeat catheter-directed angiography revealed a striking reversal of cerebral large vessel arteriopathy. This article reveals a previously unrecognized and potentially beneficial effect of HSCT that may ameliorate cerebral large vessel arteriopathy and improve cerebrovascular health for children with SCD.
Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals
Jack, Clifford R. , Wiste, Heather J. , Weigand, Stephen D. , Lowe, Val J. , Vemuri, Prashanthi , Graff‐Radford, Jonathan , Fields, Julie A. , Therneau, Terry M. , Petersen, Ronald C. , Figdore, Dan J, Jack, Clifford R , Vemuri, Prashanthi , Algeciras‐Schimnich, Alicia , Figdore, Daniel J. , Ramanan, Vijay K. , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Schwarz, Christopher G. , Cogswell, Petrice M. , Senjem, Matthew L.

Alzheimer's & Dementia | January 24, 2024 | Volume: 20 | Issue: 3 | Pages: 2143-2154

10.1002/alz.13651 | PMID 38265198 Get It

Abstract BACKGROUND We compared the ability of several plasma biomarkers versus amyloid positron emission tomography (PET) to predict rates of memory decline among cognitively unimpaired individuals. METHODS We studied 645 Mayo Clinic Study of Aging participants. Predictor variables were age, sex, education, apolipoprotein E ( APOE ) ε 4 genotype, amyloid PET, and plasma amyloid beta (Aβ)42/40, phosphorylated tau (p‐tau)181, neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and p‐tau217. The outcome was a change in a memory composite measure. RESULTS All plasma biomarkers, except NfL, were associated with mean memory decline in models with individual biomarkers. However, amyloid PET and plasma p‐tau217, along with age, were key variables independently associated with mean memory decline in models combining all predictors. Confidence intervals were narrow for estimates of population mean prediction, but person‐level prediction intervals were wide. DISCUSSION Plasma p‐tau217 and amyloid PET provide useful information about predicting rates of future cognitive decline in cognitively unimpaired individuals at the population mean level, but not at the individual person level.
The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification
Wang, Haitao , Pignolo, Robert J. , Wang, Haitao , Kaplan, Frederick S.

Biomolecules | January 24, 2024 | Volume: 14 | Issue: 2 | Pages: 147

10.3390/biom14020147 | PMID 38397384 Get It

Fibrodysplasia ossificans progressiva (FOP; MIM# 135100) is an ultra-rare congenital disorder caused by gain-of-function point mutations in the Activin receptor A type I (ACVR1, also known as ALK2) gene. FOP is characterized by episodic heterotopic ossification (HO) in skeletal muscles, tendons, ligaments, or other soft tissues that progressively causes irreversible loss of mobility. FOP mutations cause mild ligand-independent constitutive activation as well as ligand-dependent bone morphogenetic protein (BMP) pathway hypersensitivity of mutant ACVR1. BMP signaling is also a key pathway for mediating acquired HO. However, HO is a highly complex biological process involving multiple interacting signaling pathways. Among them, the hypoxia-inducible factor (HIF) and mechanistic target of rapamycin (mTOR) pathways are intimately involved in both genetic and acquired HO formation. HIF-1α inhibition or mTOR inhibition reduces HO formation in mouse models of FOP or acquired HO in part by de-amplifying the BMP pathway signaling. Here, we review the recent progress on the mechanisms of the HIF-1α and mTOR pathways in the amplification of HO lesions and discuss the future directions and strategies to translate the targeting of HIF-1α and the mTOR pathways into clinical interventions for FOP and other forms of HO.